
Klygefa Approved: Weekly C5 Autoinjector for Myasthenia Gravis
FDA approved AstraZeneca’s Klygefa, a weekly self injected C5 inhibitor for AChR positive myasthenia gravis. What PREVAIL showed and what is still unknown.

FDA approved AstraZeneca’s Klygefa, a weekly self injected C5 inhibitor for AChR positive myasthenia gravis. What PREVAIL showed and what is still unknown.

Why a biosimilar can win FDA approval years before launch: the BPCIA patent dance, 12 year exclusivity, settlements and what Biocon’s Pebrilzo deal shows.

The FDA rejected Summit’s ivonescimab on November 15, 2026, ruling that a PFS benefit in EGFR mutated NSCLC cannot stand in for a significant survival win.

An FDA complete response letter means a drug or biologic will not be approved as submitted. What a CRL must contain, the sponsor’s options and the clocks.

FDA issued a complete response letter for Summit’s ivonescimab in EGFR mutated lung cancer, disclosed Nov 15, 2026, citing no statistically significant OS gain.

FDA approved Imfinzi plus Padcev before surgery for cisplatin ineligible bladder cancer on Nov. 13, 2026, as VOLGA showed an EFS hazard ratio of 0.51.

Project Orbis lets FDA and eight partner regulators review cancer drug applications at the same time. Here is how it works, who joins, and how sponsors use it.

Reuters reports FDA has shelved its national priority voucher pilot; HHS says it is ongoing. What 22 voucher holders and nine pending reviews face now.

A PDUFA date is FDA’s goal to act on a drug application. How the clock is set, when it extends by three months, and what happens on decision day.

enGene rose 26.7% on November 12, 2026 after LEGEND showed 12 month bladder cancer complete responses rising to 24% from 13%, against a 3.3% biotech selloff.